{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:32:05Z","timestamp":1759969925240,"version":"build-2065373602"},"reference-count":81,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.maturitas.2006.01.011","type":"journal-article","created":{"date-parts":[[2006,3,8]],"date-time":"2006-03-08T07:21:46Z","timestamp":1141802506000},"page":"1-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Oral ibandronate in the management of postmenopausal osteoporosis: Review of upper gastrointestinal safety"],"prefix":"10.1016","volume":"54","author":[{"given":"Sol","family":"Epstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre D.","family":"Delmas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Emkey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie M.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Hiltbrunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph C.","family":"Schimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2A","key":"10.1016\/j.maturitas.2006.01.011_bib1","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0002-9343(05)80037-3","article-title":"The economic and human costs of osteoporotic fracture","volume":"98","author":"Barrett-Connor","year":"1995","journal-title":"Am J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.maturitas.2006.01.011_bib2","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/PL00004164","article-title":"Bisphosphonates: pharmacology, mechanisms of action and clinical uses","volume":"9","author":"Russell","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2006.01.011_bib3","first-page":"3109","article-title":"Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women","volume":"85","author":"Tonino","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2006.01.011_bib4","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten-years\u2019 experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"New Engl J Med"},{"key":"10.1016\/j.maturitas.2006.01.011_bib5","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"de Groen","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2006.01.011_bib6","first-page":"1377","article-title":"Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis","volume":"4","author":"Ettinger","year":"1998","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.maturitas.2006.01.011_bib7","first-page":"488","article-title":"Alendronate use among 812 women: prevalence of gastrointestinal complaints, non-compliance with patient instructions, and discontinuation","volume":"4","author":"Ettinger","year":"1998","journal-title":"J Manag Care Pharm"},{"issue":"Suppl. 1","key":"10.1016\/j.maturitas.2006.01.011_bib8","first-page":"S469","article-title":"Side effect profile of alendronate in clinical practice","volume":"12","author":"Daoud","year":"1997","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2006.01.011_bib9","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1136\/bmj.315.7117.1235a","article-title":"Incidence of gastrointestinal side effects due to alendronate is high in clinical practice","volume":"315","author":"Kelly","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.maturitas.2006.01.011_bib10","first-page":"51","article-title":"The clinical tolerability profile of alendronate","volume":"101","author":"Watts","year":"1999","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.maturitas.2006.01.011_bib11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1001\/archinte.160.4.517","article-title":"Upper gastrointestinal safety profile of alendronate. The Fracture Intervention Trial","volume":"160","author":"Bauer","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.maturitas.2006.01.011_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1385\/JCD:6:1:45","article-title":"Bone density changes with once weekly risedronate in postmenopausal women","volume":"6","author":"Delaney","year":"2003","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.maturitas.2006.01.011_bib13","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1359\/jbmr.1998.13.6.1032","article-title":"Risedronate in the treatment of Paget's disease of bone: an open-label, multicenter study","volume":"13","author":"Siris","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2006.01.011_bib14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF01622190","article-title":"Pamidronate: an unrecognised problem in gastrointestinal tolerability","volume":"4","author":"Lufkin","year":"1994","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2006.01.011_bib15","first-page":"961","article-title":"Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone","volume":"81","author":"Siris","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2006.01.011_bib16","first-page":"631","article-title":"Bisphosphonates in the management of postmenopausal osteoporosis","volume":"vol. 2","author":"Papapoulos","year":"2001"},{"key":"10.1016\/j.maturitas.2006.01.011_bib17","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/jbmr.5650060915","article-title":"BM 21.0955, a potent new bisphosphonate to inhibit bone resorption","volume":"6","author":"M\u00fchlbauer","year":"1991","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2006.01.011_bib18","first-page":"1426","article-title":"Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date","volume":"166","author":"Hodsman","year":"2002","journal-title":"CMAJ"},{"key":"10.1016\/j.maturitas.2006.01.011_bib19","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1023\/A:1016495221567","article-title":"What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates","volume":"47","author":"Graham","year":"2002","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.maturitas.2006.01.011_bib20","first-page":"1282","article-title":"Alendronate-induced ulcerative esophagitis","volume":"91","author":"Abdelmalek","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.maturitas.2006.01.011_bib21","first-page":"1889","article-title":"Multiple ulcerative esophagitis caused by alendronate","volume":"90","author":"Maconi","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.maturitas.2006.01.011_bib22","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(05)64955-0","article-title":"Oesophageal stricture associated with alendronic acid","volume":"348","author":"Naylor","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2006.01.011_bib23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1055\/s-2007-1005544","article-title":"Esophageal ulceration due to alendronate","volume":"28","author":"Sorrentino","year":"1996","journal-title":"Endoscopy"},{"key":"10.1016\/j.maturitas.2006.01.011_bib24","first-page":"704","article-title":"A new probable increasing cause of esophageal ulceration: alendronate","volume":"92","author":"Colina","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.maturitas.2006.01.011_bib25","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0016-5107(97)70018-X","article-title":"Esophagitis dissecans superficialis and alendronate: case report","volume":"46","author":"Cameron","year":"1997","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.maturitas.2006.01.011_bib26","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0002-9343(97)89446-6","article-title":"Esophageal stricture associated with alendronate therapy","volume":"102","author":"Levine","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.maturitas.2006.01.011_bib27","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1148\/radiology.206.2.9457190","article-title":"Alendronate-induced esophagitis: case report of a recently recognized form of severe esophagitis with esophageal stricture\u2014radiographic features","volume":"206","author":"Ryan","year":"1998","journal-title":"Radiology"},{"key":"10.1016\/j.maturitas.2006.01.011_bib28","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0016-5107(98)70256-1","article-title":"Alendronate-associated esophagitis: endoscopic and pathologic features","volume":"47","author":"Ribeiro","year":"1998","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.maturitas.2006.01.011_bib29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1053\/gast.2000.16517","article-title":"Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women","volume":"119","author":"Lanza","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.maturitas.2006.01.011_bib30","article-title":"Incidence of gastric ulcers lower in postmenopausal women treated with risedronate than alendronate, regardless of H. pylori status","volume":"53","author":"Thomson","year":"2001","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.maturitas.2006.01.011_bib31","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4065\/77.10.1031","article-title":"Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?","volume":"77","author":"Cryer","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.maturitas.2006.01.011_bib32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/1099-1557(200009\/10)9:5<367::AID-PDS515>3.0.CO;2-O","article-title":"Proportion of osteoporotic post-menopausal women at increased risk for upper GI adverse events associated with bisphosphonate therapy","volume":"9","author":"Levine","year":"2000","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.maturitas.2006.01.011_bib33","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1023\/A:1018849415297","article-title":"Non-clinical model for assessing gastric effects of bisphosphonates","volume":"42","author":"Blank","year":"1997","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.maturitas.2006.01.011_bib34","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0024-3205(97)01040-0","article-title":"Alendronate induces gastric injury and delays ulcer healing in rodents","volume":"62","author":"Elliott","year":"1998","journal-title":"Life Sci"},{"key":"10.1016\/j.maturitas.2006.01.011_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1001\/archinte.161.1.107","article-title":"Alendronate and naproxen are synergistic for development of gastric ulcers","volume":"161","author":"Graham","year":"2001","journal-title":"Arch Intern Med"},{"issue":"Suppl. 9","key":"10.1016\/j.maturitas.2006.01.011_bib36","first-page":"S199","article-title":"Alendronate (Fosamax) interactions with non-steroidal anti-inflammatory agents: a dangerous combination?","volume":"43","author":"Rothschild","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.maturitas.2006.01.011_bib37","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2006.01.011_bib38","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.maturitas.2006.01.011_bib39","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2006.01.011_bib40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2006.01.011_bib41","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2006.01.011_bib42","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2006.01.011_bib43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.maturitas.2006.01.011_bib44","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4065\/77.3.262","article-title":"Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials","volume":"77","author":"Taggart","year":"2002","journal-title":"Mayo Clin Proc"},{"issue":"Suppl. 2","key":"10.1016\/j.maturitas.2006.01.011_bib45","first-page":"S260","article-title":"An observational study of the incidence of GI events among patients receiving treatment with a bisphosphonate","volume":"18","author":"Worley","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2006.01.011_bib46","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/BF03351502","article-title":"Tolerability of risedronate in postmenopausal women intolerant of alendronate","volume":"13","author":"Adachi","year":"2001","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.maturitas.2006.01.011_bib47","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0149-2918(00)83042-8","article-title":"Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms","volume":"22","author":"Miller","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.maturitas.2006.01.011_bib48","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1185\/030079903125002009","article-title":"Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study","volume":"19","author":"Hosking","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.maturitas.2006.01.011_bib49","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1359\/JBMR.040920","article-title":"Treatment with once-weekly alendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: a randomized double-blind study","volume":"20","author":"Rosen","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2006.01.011_bib50","doi-asserted-by":"crossref","DOI":"10.2165\/00002512-199404060-00002","article-title":"Polypharmacy in the aged. Practical solutions","volume":"4","author":"Stewart","year":"1994","journal-title":"Drugs Aging"},{"issue":"Suppl. 7","key":"10.1016\/j.maturitas.2006.01.011_bib51","first-page":"S2","article-title":"Clinical and economic impact of adherence to osteoporosis medication","volume":"14","author":"Caro","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2006.01.011_bib52","first-page":"408","article-title":"Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density: the IMPACT study","volume":"72","author":"Eastell","year":"2003","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.maturitas.2006.01.011_bib53","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00198-003-1502-4","article-title":"Compliance with pharmacologic therapy for osteoporosis","volume":"14","author":"Yood","year":"2003","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.maturitas.2006.01.011_bib54","first-page":"1917","article-title":"Using medications appropriately in older adults","volume":"66","author":"Williams","year":"2002","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.maturitas.2006.01.011_bib55","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0149-2918(02)80085-6","article-title":"Patient preference for once-weekly alendronate 70mg versus once-daily alendronate 10mg: a multicenter, randomized, open-label, crossover study","volume":"24","author":"Simon","year":"2002","journal-title":"Clin Ther"},{"key":"10.1016\/j.maturitas.2006.01.011_bib56","first-page":"711","article-title":"Therapeutic equivalence of alendronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis","volume":"101","author":"Luckey","year":"2003","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.maturitas.2006.01.011_bib57","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","article-title":"Two-year results of once-weekly administration of alendronate 70mg for the treatment of postmenopausal osteoporosis","volume":"17","author":"Rizzoli","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2006.01.011_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03339822","article-title":"Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily for the treatment of osteoporosis","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging Clin Exp Res"},{"key":"10.1016\/j.maturitas.2006.01.011_bib59","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.maturitas.2006.01.011_bib60","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1210\/jc.2003-022029","article-title":"Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis","volume":"88","author":"Cooper","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.maturitas.2006.01.011_bib61","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0149-2918(00)87974-6","article-title":"Weekly administration of alendronate: rationale and plan for clinical assessment","volume":"22","author":"Bone","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.maturitas.2006.01.011_bib62","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S8756-3282(01)00589-0","article-title":"Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity","volume":"29","author":"Suri","year":"2001","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2006.01.011_bib63","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1023\/A:1005574009856","article-title":"Effect of bisphosphonates on the surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa","volume":"45","author":"Lichtenberger","year":"2000","journal-title":"Dig Dis Sci"},{"year":"2003","series-title":"Principles of anatomy and physiology","author":"Tortora","key":"10.1016\/j.maturitas.2006.01.011_bib64"},{"key":"10.1016\/j.maturitas.2006.01.011_bib65","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1023\/A:1018894827961","article-title":"Esophageal irritation due to alendronate sodium tablets: possible mechanisms","volume":"43","author":"Peter","year":"1998","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.maturitas.2006.01.011_bib66","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/er.2001-9002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1016\/j.maturitas.2006.01.011_bib67","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2006.01.011_bib68","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S8756-3282(96)00229-3","article-title":"The effect of bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study","volume":"19","author":"Ravn","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2006.01.011_bib69","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1359\/jbmr.2001.16.10.1871","article-title":"Ibandronate: a comparison of oral daily versus intermittent dosing in postmenopausal osteoporosis","volume":"16","author":"Riis","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2006.01.011_bib70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.0301202","article-title":"Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis","volume":"19","author":"McClung","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.maturitas.2006.01.011_bib71","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2796.2003.01174.x","article-title":"Oral weekly ibandronate prevents bone loss in postmenopausal women","volume":"254","author":"Tank\u00f3","year":"2003","journal-title":"J Intern Med"},{"issue":"Suppl. 9","key":"10.1016\/j.maturitas.2006.01.011_bib72","article-title":"Favorable upper gastrointestinal safety profile of ibandronate in patients with a history of gastrointestinal disorders or receiving concomitant NSAIDs","volume":"48","author":"Rosen","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.maturitas.2006.01.011_bib73","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2217\/14750708.2.2.179","article-title":"Ibandronate: a new perspective in the treatment of osteoporosis","volume":"2","author":"Reginster","year":"2005","journal-title":"Therapy"},{"key":"10.1016\/j.maturitas.2006.01.011_bib74","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S8756-3282(03)00033-4","article-title":"The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60min before breakfast","volume":"32","author":"Tank\u00f3","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2006.01.011_bib75","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(03)00091-7","article-title":"Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens","volume":"32","author":"Tank\u00f3","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.maturitas.2006.01.011_bib76","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1023\/A:1008386501738","article-title":"Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease","volume":"10","author":"Coleman","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1016\/j.maturitas.2006.01.011_bib77","first-page":"47","article-title":"Oral daily ibandronate in women with metastatic breast cancer: a pooled safety analysis","volume":"22","author":"Diel","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.maturitas.2006.01.011_bib78","first-page":"293","article-title":"American Association of Clinical Endocrinologists 2001: medical guidelines for clinical practice for the prevention and management of postmenopausal osteoporosis","volume":"7","author":"Hodgson","year":"2001","journal-title":"Endocr Pract"},{"key":"10.1016\/j.maturitas.2006.01.011_bib79","first-page":"31","article-title":"Bisphosphonate dosing preferences in women with postmenopausal osteoporosis: a study","volume":"30","author":"Simon","year":"2005","journal-title":"The Female Patient"},{"key":"10.1016\/j.maturitas.2006.01.011_bib80","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1742-1241.2003.tb10518.x","article-title":"Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis","volume":"57","author":"Papapoulos","year":"2003","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.maturitas.2006.01.011_bib81","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0149-2918(03)90005-1","article-title":"Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies","volume":"25","author":"Schimmer","year":"2003","journal-title":"Clin Ther"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512206000570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512206000570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:40:47Z","timestamp":1759912847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512206000570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S0378512206000570"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2006.01.011","relation":{},"ISSN":["0378-5122"],"issn-type":[{"type":"print","value":"0378-5122"}],"subject":[],"published":{"date-parts":[[2006,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral ibandronate in the management of postmenopausal osteoporosis: Review of upper gastrointestinal safety","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2006.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}